US FDA cGMP warning letters may follow import alerts
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration has clarified that it does not necessarily have to stick to its generally known approach of sending warning letters to companies that have failed to meet current good manufacturing practice standards, ahead of issuing a full-blown import alert.